To report the efficacy and tolerability of brivaracetam (BRV) in add-on therapy in pediatric patients with severe drug-resistant epilepsy. Prognostic factors of clinical outcome were also analyzed.
Russo, A., Pruccoli, J., Cesaroni, C.A., Belotti, L.M.B., Zenesini, C., Bonanni, P., et al. (2022). Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence. SEIZURE, 102, 120-124 [10.1016/j.seizure.2022.10.001].
Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence
Russo, Angelo
;Pruccoli, Jacopo;Cesaroni, Carlo Alberto;Belotti, Laura Maria Beatrice;Zenesini, Corrado;Cordelli, Duccio Maria;
2022
Abstract
To report the efficacy and tolerability of brivaracetam (BRV) in add-on therapy in pediatric patients with severe drug-resistant epilepsy. Prognostic factors of clinical outcome were also analyzed.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
